Patents by Inventor Sarah S. Bacus

Sarah S. Bacus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190219581
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 18, 2019
    Applicants: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Publication number: 20180080087
    Abstract: The present disclosure provides method for determining an immune response score (irScore), the method comprising: determining a number of differentially expressed genes that have are implicated in anti-tumor immune cell signaling/activation; determining a number of differentially expressed genes that are implicated in immunosuppression, wherein the irScore=X(low, medium, or high), wherein X is the number of differentially expressed genes that are implicated in anti-tumor immune cell signaling/activation, and wherein low refers to 1-4 differentially expressed genes that are implicated in immunosuppression, medium refers to 5-9 differentially expressed genes that are implicated in immunosuppression, and high refers to 10 or more differentially expressed genes that are implicated in immunosuppression.
    Type: Application
    Filed: September 15, 2017
    Publication date: March 22, 2018
    Inventors: Sarah S. Bacus, Christopher A. Hamm
  • Publication number: 20180031559
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Applicants: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 9625446
    Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: April 18, 2017
    Assignee: Ventana Medical Systems, Inc.
    Inventor: Sarah S. Bacus
  • Publication number: 20160091493
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: December 10, 2015
    Publication date: March 31, 2016
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 9239331
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: January 19, 2016
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Publication number: 20150125448
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: January 13, 2015
    Publication date: May 7, 2015
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 8956822
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: February 17, 2015
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 8709738
    Abstract: Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for determining whether a potential drug is likely to produce a cardiotoxic effect. The methods involve analyzing lipid levels or the expression fatty acid oxidation enzymes, pAMP activated protein kinase, glucose uptake, to determine whether a fatty acid oxidation disorder is present. The identification of a fatty acid oxidation disorder can be used as a predictor of toxicity, especially cardiac toxicity, and as an indication that organ function should be carefully monitored if a drug such as a tyrosine kinase inhibitor is administered. Methods are also disclosed for protecting organs from metabolic stress and for the treatment of cells, such as adipocytes, to reduce their lipid content.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: April 29, 2014
    Assignee: Quintiles Transnational Corporation
    Inventor: Sarah S. Bacus
  • Publication number: 20130302829
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 14, 2013
    Applicants: Cell Signaling Technology, Inc., Ventana Medical Systems, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Publication number: 20130225424
    Abstract: The present disclosure provides methods for predicting the sensitivity (e.g., responsiveness) of a cell and/or biological sample obtained from a subject (e.g., a human) to a drug (e.g., a DHFR inhibitor). Such methods may comprise determining the presence or absence of one or more Ras mutations and/or determining the presence or absence of an amplification of the Ras gene in the cell and/or biological sample. The methods may be used to predict the responsiveness of a subject to treatment with a drug.
    Type: Application
    Filed: March 3, 2011
    Publication date: August 29, 2013
    Applicant: Targeted Molecular Diagnostics, LLC
    Inventor: Sarah S. Bacus
  • Patent number: 8512967
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: August 20, 2013
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Publication number: 20110136149
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 9, 2011
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 7862995
    Abstract: The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: January 4, 2011
    Assignee: Targeted Molecular Diagnostics
    Inventors: Sarah S. Bacus, Jason Hill
  • Publication number: 20100332417
    Abstract: The present disclosure relates generally to methods for the detection and quantitation of the p95 component of HER2/neu (ERbB2). Such methods may comprise assaying the biological sample for expression of HER2 ICD; assaying the biological sample for expression of a HER2 ECD; quantitating an expressed amount of the HER2 ICD and an expressed amount of the HER2 ECD in the biological sample; and determining the amount of p95 expressed in the biological sample based on a difference between the expressed amount of the HER2 ICD and the expressed amount of the HER2 ECD. The methods of the present disclosure may be used to predict whether a subject will be responsive to a receptor tyrosine kinase inhibitor and/or may be used to select subjects for inclusion/exclusion in a clinical trial.
    Type: Application
    Filed: June 2, 2010
    Publication date: December 30, 2010
    Applicant: TARGETED MOLECULAR DIAGNOSTICS, LLC
    Inventor: Sarah S. Bacus
  • Publication number: 20100303809
    Abstract: The present disclosure provides methods for determining if PTEN is elevated or reduced in one or more tumor cells relative to one or more normal cells in the same biological sample by obtaining a biological sample comprising one or more tumor cells and one or more normal cells; assaying the biological sample for expression of PTEN; quantitating an amount of PTEN expression in the one or more tumor cells and an amount of PTEN expression in the one or more normal cells; comparing the amount of PTEN expression in the tumor cells to the amount of PTEN expression in the normal cells; and determining that PTEN is elevated in the tumor cells where the amount of expression of PTEN is greater in the tumor cells as compared to the normal cells or determining that PTEN is reduced in the tumor cells where the amount of expression of PTEN is less in the tumor cells than in the normal cells.
    Type: Application
    Filed: June 1, 2010
    Publication date: December 2, 2010
    Applicant: TARGETED MOLECULAR DIAGNOSTICS, LLC
    Inventor: Sarah S. Bacus
  • Patent number: 7833698
    Abstract: The invention relates to a method for determining the response to cancer therapy in an individual using image analysis.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: November 16, 2010
    Assignee: Ventana Medical Systems, Inc.
    Inventor: Sarah S. Bacus
  • Publication number: 20100279323
    Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual.
    Type: Application
    Filed: June 29, 2010
    Publication date: November 4, 2010
    Inventors: Sarah S. BACUS, David Haskett LYNCH, Pamela LOCKBAUM, Gisela SCHWAB, Xiao-dong YANG
  • Patent number: 7771958
    Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 10, 2010
    Assignee: Amgen Inc.
    Inventors: Sarah S. Bacus, David Haskett Lynch, Pamela Lockbaum, Gisela Schwab, Xiao-dong Yang
  • Publication number: 20090318346
    Abstract: A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding molecules act as traps to bind and sequester ligands, thus making them unavailable for binding to cellular ErbB receptors.
    Type: Application
    Filed: February 8, 2007
    Publication date: December 24, 2009
    Applicants: Targeted Molecular Diagnostics, Yeda Research and Development Co., Ltd.
    Inventors: Sarah S. Bacus, Jason E. Hill, Josef Yarden, Bose S. Kochupurakkal